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Clinical Characteristics of Coronary Drug-Eluting Stent Fracture: 
Insights from a Two-Center DES Registry
Stent fracture (SF) has been implicated as a risk factor for in-stent restenosis, but its 
incidence and clinical characteristics are not well established. Therefore we investigated the 
conditions associated with stent fracture and its clinical presentation and outcome. 
Between 2004 and 2007, consecutive cases of SF were collected from the Seoul National 
University Hospital. Clinical characteristics and outcome of patients with fractured stents 
were compared with a ten-fold cohort of age and gender matched controls (n = 236). A 
total of 4,845 patients received percutaneous coronary intervention and 3,315 patients 
(68.4%) underwent angiographic follow-up. Twenty-eight fractured stents were observed 
in 24 patients. The incidence of SF was 0.89% for sirolimus-eluting stents (SES) and 0.09% 
for paclitaxel-eluting stents. Chronic kidney disease, stent implantation in the right 
coronary artery (RCA), and SES use were independent predictors of drug-eluting stent 
fracture by multivariate analysis. SF was significantly associated with binary restenosis 
(11.4% vs 41.7%, P < 0.001) and increased risk of target lesion revascularization (8.1% vs 
33.3%, P = 0.001). Patients with SF but without significant restenosis showed excellent 
outcome despite only medical treatment. In conclusion, SF is associated with increased 
rates of restenosis and repeat revascularization. Significant risk factors include chronic 
kidney disease, RCA intervention, and SES use.
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ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
The development of the drug-eluting stent (DES) has revolu-
tionized the field of interventional cardiology by significantly 
reducing the restenosis rates and need for repeat revasculariza-
tion (1-4). However, fracture of stent struts in a DES with conse-
quent interruption may lead to insufficient drug delivery result-
ing in attenuated inhibition of neointimal formation and reste-
nosis. Stent fracture was not a big concern in the bare metal stent 
(BMS) era because neointima formation and restenosis were a 
much more frequent phenomenon and investigators were not 
focused on evaluating the angiography for possible disruptions 
in stent struts. Furthermore, the greater neointimal coverage in 
the early stages of post-stent implantation could have protected 
struts from occurrence of fracture in the BMS era (5, 6).
  In the present study, we investigated the conditions associat-
ed with stent fracture and the clinical consequences of stent frac-
ture by consecutive analysis of percutaneous coronary interven-
tion (PCI) cases performed at two major cardiovascular centers 
in Korea. We also analyzed possible factors associated with bi-
nary restenosis in lesions with fractured stent struts.
MATERIALS AND METHODS
Patients
We reviewed consecutive PCI cases performed between June 
2004 and December 2007 at Seoul National University Hospital 
and Bundang Hospital. A total of 4845 patients received PCI 
during this period, where 4,132 sirolimus-eluting stents (SES) 
(CYPHER
® Stent, Cordis Corporation, a Johnson & Johnson 
Company, Warren, NJ, USA) and 2,966 paclitaxel-eluting stents 
(PES) (TAXUS
®, Boston Scientific Cooperation, Boston, MA, Park KW, et al.  •  Drug-eluting Stent Fracture
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USA) were implanted. Of these patients, 3,315 patients (68.42%) 
received routine angiographic follow-up between 6 to 12 months 
post-PCI.
  The patients with stent fracture were matched 10-fold with 
age- and gender-matched controls. Clinical, angiographic, and 
procedural information were recorded and follow-up report on 
angiographies and procedures were available for all patients 
since we closely monitor all our PCI patients. In addition, we 
collected the follow-up data after detection of stent fracture in 
these patients for at least an additional 9 months. Median fol-
low-up duration of patients with fractured stents was 30 (24.5-
37.5) months since index PCI, and 23 (16.25-27.75) months 
since diagnosis of stent strut fracture, respectively. All medical 
records were reviewed by independent clinical data managers 
that were unaware of the purpose of the study. 
Definitions
Stent fracture was defined as the presence of an angiographi-
cally visible interrupted connection of stent struts or fewer visi-
ble stent struts at the suspected site than normal looking stent-
ed area on intravascular ultrasound. Binary restenosis was de-
fined as in-segment diameter stenosis greater than 50%, and 
target lesion revascularization (TLR) as repeated revasculariza-
tion of a previously implanted stent with binary restenosis. 
Procedure
We performed PCI according to the standard guidelines. The 
choice between sirolimus-eluting stents and paclitaxel-eluting 
stents was up to the operators’ discretion as well as performing 
pre- and post-dilatation for optimal stent expansion, and the 
use of glycoprotein IIb/IIIa antagonists. A loading dose of 300 
mg aspirin and 300-600 mg clopidogrel was administered prior 
to PCI. All patients were recommended to take aspirin indefi-
nitely and clopidogrel for at least 6 months post-PCI.
Statistics
Data was presented as numbers and frequencies for categorical 
variables, and mean ± standard deviation for continuous vari-
ables. For comparison between fractured stents with age gen-
der matched controls, chi-square and Fisher’s exact test were 
used for categorical variables and Student’s t-test for continu-
ous variables. For comparison within the fractured stent group, 
we applied non-parametric Mann-Whitney U test for continu-
ous variables. A multivariate logistic regression analysis was 
used to identify independent predictors of stent fracture. Statis-
tical tests were performed using SPSS version 17 (SPSS Inc., 
Chicago, IL, USA).
Ethics statement
The study was approved by the institutional review board of 
Seoul National University Hospital (IRB Number: H-1006-104-
322). Informed consent was exempted by the board.  
RESULTS
Incidence of stent fracture 
Twenty eight fractured struts in 26 stents were observed in 24 of 
3315 patients (one patient had two fractured struts in one SES, 
another patient had 3 fractured struts in 2 overlapped SES, a 
third had one fractured strut in each of the 2 implanted stents). 
The location of fracture was 34.6% in left anterior descending 
artery (LAD), 11.5% in left circumflex artery (LCX), and 53.8% 
in right coronary artery (RCA) respectively. As for the severity of 
stent fracture, there were 13 type I fractures (50%), 2 type II frac-
tures (7.7%), 10 type III fractures (38.4%), and 1 type IV fracture 
(3.9%), and 0 type V fracture according to stent fracture grading 
(7). Therefore the incidence of stent fracture was 0.52% (26 of 
Table 1. Baseline clinical, procedural characteristics
Variables SF (-) (n = 236) SF (+) (n = 24) P value
Age, years, mean ± SD   63.8 ± 11.5   63.5 ± 11.6 0.895
Male  226 (95.8%)   23 (95.8%) 1.000
Diabetes    78 (33.1%)    10 (41.7%) 0.497
Hypertension  148 (62.7%)    20 (83.8%) 0.044*
Chronic renal failure    8 (3.4%)      5 (20.8%) 0.003*
Current smoker    78 (33.1%)   6 (25%) 0.422
Dyslipidemia    97 (41.1%)    13 (54.2%) 0.217
Diagnosis at index PCI
   Stable angina
   UA/NSTEMI
   STEMI
   Variant angina
   Silent ischemia
   Claudication
   89 (37.7%)
 111 (47.0%)
 22 (9.3%)
0 (0%)
 14 (5.9%)
0 (0%)
10 (42%)
     8 (33.3%)
     4 (16.7%)
   1 (4.2%)
0 (0%)
   1 (4.2%)
0.704
0.199
0.253
0.092
0.376
0.092
Location of stented Vessel  
   at index PCI
   LM
   LAD
   LCX
   RCA
   Total*
   4 (1.0%)
 181 (47.9%)
   86 (22.8%)
 107 (28.3%)
378 (100%)
0 (0%) 
20 (37%)
     8 (14.8%)
   26 (48.2%)
  54 (100%)
1.000
0.150
0.135
0.003*
Implanted stent number per  
  lesion
   SES
   PES
   ZES
   Total DES
   BMS
   Total stent
  1.39±0.31
    1.6±0.86
  1.50±0.83
  1.61±0.90
  1.22±0.44
  1.63±0.91
  2.05±0.89
  1.75±0.95
  0±0
    2.17±0.197
    1.0±0.00
  2.25±0.89
< 0.001*
0.739
NA
0.005*
0.511
0.002*
Stent size
   Mean diameter, mm ± SD
   Minimum diameter, mm ± SD
   Total length, mm ± SD
   Max. inflation pressure,  
       atm ± SD
  3.10±0.36
  3.01±0.39
  40.07±25.51
11.62±3.39
  3.09±0.34
  2.81±0.63
  55.25±22.26
13.42±3.86
0.912
0.028*
0.005*
0.015*
*Numbers are rounded and may not total 100%. BMS, bare metal stent; DES, drug-
eluting stent; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left 
main artery; Max. inflation pressure, maximal inflation pressure (atm);  NSTEMI, non-
ST elevation myocardial infarction; PES, paclitaxel-eluting stent; RCA, right coronary 
artery; SES, sirolimus-eluting stent; UA, unstable angina; ZES, zotarolimus-eluting 
stent.Park KW, et al.  •  Drug-eluting Stent Fracture
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4993 stents) in total but there was a preponderance for stent 
fracture in SES (0.89%, 24 of 2709 SES) compared with the PES 
(0.09%, 2 of 2284 PES). Most cases (21 of 24) were detected dur-
ing asymptomatic routine surveillance angiography between 6 
to 12 months after index PCI, while 3 patients received coronary 
angiography for evaluation of chest pain.
Baseline characteristics and risk factors of stent fracture
To find characteristics associated with stent fracture, the 24 pa-
tients with stent fracture were matched 10-fold with age- and 
gender-matched controls. Ten age- and gender-matched con-
trol patients per stent fracture patient was possible in all but one 
patient (n = 230). Only six matching controls could be identified 
for that one individual and thus characteristics of 24 patients 
with stent fracture were compared with 236 age- and gender-
matched controls. The baseline clinical and procedural charac-
teristics of the patients with stent fracture compared with those 
without stent fracture are shown in Table 1. Baseline clinical 
characteristics were mostly comparable between the two groups. 
Hypertension (62.7% vs 83.8%, P = 0.044) and chronic kidney 
disease (3.4% vs 20.8%, P = 0.003) were more common in the 
stent fracture group. No difference was found regarding the ini-
tial diagnosis necessitating stent implantation.
  As for angiographic and procedural characteristics, there were 
several differences. The average number of implanted stents 
was greater (2.17 ± 0.19 vs 1.61 ± 0.91, P = 0.005), the total stent 
length longer, (55.25 ± 22.26 mm vs 40.07 ± 25.51 mm, P = 0.005), 
and the maximal stent inflation pressure higher (13.42 ± 3.86 
atm vs 11.62 ± 3.39 atm, P = 0.015) in the stent fracture group 
compared with the control group.
  Although the distribution of implanted stents in the control 
group was 47.9% in LAD, 22.8% in LCX and 28.3% in RCA, the 
distribution of fractured stents in the stent fracture group was 
34.6% in LAD, 11.5% in LCX, and 53.8% in RCA respectively, sug-
gesting that stent fracture was more prevalent in RCA implant-
ed stents.
  To find independent predictors of DES fracture, we performed 
a logistic multivariate analysis entering previously reported risk 
factors of stent fracture such as total stent length, SES, minimum 
stent diameter, maximal inflation pressure (5, 8, 9) along with 
variables that were found to be significant in univariate analysis 
in the present cohort. On multivariate analysis, we found that 
chronic kidney disease, stent implantation in the RCA, and SES 
were independent predictors of DES fracture (Table 2).
Clinical presentation at stent fracture diagnosis
We compared the clinical and angiographic presentation of those 
that had stent fracture versus those that did not. At the time of 
angiographic follow-up (where the diagnosis of stent fracture 
was possible), clinical presentation of patients with fractured 
stents did not differ from those without stent fracture. The sever-
ity of angina according to Canadian Cardiovascular Society (CCS) 
Functional Classification and the incidence of acute coronary 
syndrome (ASC) were not different in both groups (CCS ≤ 1: 
94.5% vs 87.5%, P = 0.174, CCS ≥ 2: 1.7% vs 8.3%, P = 0.097, in-
cluding unstable angina/non-ST elevation myocardial infarc-
tion (NSTEMI) 2.5% vs 4.2%, P = 0.497, STEMI 0.4% vs 0%, P = 
1.000, silent ischemia 0.4% vs 0%, P = 1.000) (Table 3). However, 
the binary restenosis rate was significantly higher in stent frac-
ture group compared with the control group (41.7% vs 11.4%, P 
< 0.001) as well as the TLR (33.3% vs 8.1%, P = 0.001) (Fig. 1). 
  Subgroup analysis of patients with fractured stents showed 
Table 2. Independent predictors of stent fracture after multivariate analysis (entering 
hypertension, chronic kidney disease, stent in RCA, SES number, minimum stent dia-
meter, maximum inflation pressure)  
  P value Odds ratio 95% Confidence interval
CRF 0.021 5.748 1.298 25.458
Stent in RCA 0.012 3.674 1.328 10.169
SES number < 0.001 3.590 2.148   5.999
CRF, chromic renal failure; RCA, right coronary artery; SES, sirolimus-eluting stent.
Table 3. Clinical presentation, angiographic finding of patients at follow up coronary 
angiography 
Findings SF (-) (n = 236) SF (+) (n = 24) P value
Diagnosis
   Stable angina, CCS 0, 1 222 (94.5%)    21 (87.5%) 0.174
   Stable angina, CCS ≥ 2   4 (1.7%)    2 (8.3%) 0.097
   UA/NSTEMI   6 (2.5%)    1 (4.2%) 0.497
   STEMI   1 (0.4%) 0 (0%) 1.000
   Silent ischemia   1 (0.4%) 0 (0%) 1.000
CAG/PCI
   Binary restenosis   27 (11.4%)    10 (41.7%) < 0.001*
   TLR 19 (8.1%)      8 (33.3%) 0.001*
CCS, Canadian Cardiovascular Society Classification; FU CAG, Follow up coronary 
angiography; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST elevation 
myocardial infarction; TLR, Target lesion revascularization; UA, unstable angina.
	 BS	 TLR
11.4
P <	0.001	 P =	0.001	
8.1
41.7
33.3
SF	(-) SF	(+)
Fig. 1. Clinical outcome of patients regarding binary restenosis (BS) and target lesion 
revascularization (TLR) rate. Patients with fractured stents (SF) have higher binary res-
tenosis and target lesion revascularization rate compared with those without fracture. Park KW, et al.  •  Drug-eluting Stent Fracture
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that all patients without binary restenosis in their fractured stents 
had CCS ≤ 1, while 2 (20%) of patients with binary restenosis com-
plained of chest pain CCS ≥ 2 and one patients presented with 
NSTEMI (Table 4, Fig. 2).
Clinical outcome of stent fracture
Among the 24 patients with fractured stents, binary restenosis 
was present in 10 patients (41.7%). Of the 10 patients, TLR was 
performed in 8 patients, where 3 patients were symptomatic 
while five were asymptomatic. The reason for performing TLR 
in those that were asymptomatic was in-stent restenosis greater 
than 70%. Of the eight patients that received TLR, three were 
treated with balloon angioplasty only, three with PES, and two 
with zotarolimus eluting stent (ZES). Of the 10 patients with bi-
nary restenosis, repeat intervention was not performed in two 
patients who showed adequate coronary flow with acceptable 
fractional flow reserve (FFR). After TLR, only 1 patient devel-
oped chest pain CCS ≥ 2. Those that received TLR showed an 
excellent clinical course with no occurrence of adverse events 
(Table 4).
  Of the 14 patients without binary restenosis despite stent frac-
ture at the time of stent fracture diagnosis, none experienced an 
adverse cardiac event. Although all 14 patients were managed 
medically without repeat PCI, no patient required TLR during 
follow up (median follow up since diagnosis of stent fracture: 
30.5 months [26.0-36.5]). 
DISCUSSION
Stent fracture is a rare complication of DES implantation. Al-
though the clinical consequence of stent fracture may be much 
milder than stent thrombosis, growing interest exists regarding 
stent fracture due to its possible association with restenosis. In 
addition, due to the increase in PCI and the large numbers of 
implanted DES, stent fracture prevalence is increasing. 
  In the present study, we found that the incidence of stent frac-
ture was relatively rare, with greater risk of stent fracture in SES. 
Amongst various univariate risk factors, chronic kidney disease, 
SES, and implantation in RCA were independent predictors of 
stent fracture. Also, stent fracture was associated with a signifi-
cantly higher risk for binary restenosis and TLR. When stent frac-
ture was not associated with significant restenosis, the progno-
sis was good with only medical follow-up. However, when as-
sociated with significant restenosis, symptoms were more likely 
to occur and thus patients received repeated procedures. 
  The first case report on DES fracture was reported by Sianos 
et al. in 2004 (9, 10). Since then, various studies have reported 
the rate of DES fracture to be between 0.84% and 3.2% (11-13). 
The overall incidence of stent fracture in this study was 0.58%, is 
therefore lower than those reported in the literature. We cannot 
rule out possible underestimation since stent fractures are not 
always easily identified during a routine coronary angiography.
  Despite this low incidence of stent fracture, more cases of stent 
fractures have been reported due to high volume of DES place-
ments, which makes now up to 90% of all implanted stents (1, 
14). Earlier studies have shown that the risk of focal restenosis is 
greater in DES with fracture. The proposed mechanism for the 
greater risk of neointimal growth in fractured stents is that when 
the stent strut becomes disrupted, sufficient sustained local drug 
delivery is not assured, and this can lead to possible focal neo-
intimal overgrowth and in-stent restenosis. Binary restenosis 
rates have been reported to be between 37.5% and 65% in frac-
Table 4. The rate of stent fracture
Clinical findings BS (-) (n = 14) BS (+) (n = 10)  P value
Presentation at stent fracture  
   diagnosis
   Stable angina, CCS 0, 1   14 (100%)   7 (70%) 0.028
   Stable angina, CCS ≥ 2 0 (0%)   2 (20%) 0.163
   UA/NSTEMI 0 (0%)   1 (10%) 0.417
   TLR 0 (0%)   8 (80%) < 0.001
   Symptoms during clinical follow 
      up after stent fracture diagnosis
   Stable angina, CCS 0, 1    13 (92.9%)   9 (90%)   1.000
   Stable angina, CCS ≥ 2 0 (0%)   1 (10%)   0.417
   Dyspnea    1 (7.1%) 0 (0%)   1.000
Follow up duration in months  
   (median, range)
   from Index PCI 30.5 [26-36.5] 28.5 [17.25-41.50]
   from SF diagnosis 23.0 [19-27.25] 17.5 [11.25-29.25]
   from TLR n.a. 14.5 [9.00-25.00]
BS, binary restenosis; CCS, Canadian Cardiology Society Functional Classification; 
NSTEMI, non ST-elevation myocardial infarction; SA, stable angina; SF, stent fracture; 
TLR, target lesion revascularization; PCI, percutaneous coronary intervention; UA, 
unstable angina.
n.s.
n.s.
P =	0.02 n.s.
CCS	0,	1 CCS	≥	2
P =	0.02
n.s.
94.50%
2%
100%
0%
70%
20%
Fig. 2. Clinical presentation at 6 month follow up CAG or stent fracture diagnosis.   
Patients with angina score CCS 0 or 1 were less common among those with stent 
fracture (SF) and binary restenosis (BS) compared with those without stent fracture or 
stent fracture without binary restenosis. CCS, Canadian Cardiology Society functional 
classification; n.s., not significant.
SF	(-)
SF(+)BS	(+)
SF(+)BS	(-)
SF	(-)
SF(+)BS	(+)2
SF(+)BS	(+)Park KW, et al.  •  Drug-eluting Stent Fracture
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tured stents, and some have suggested that DES stent fracture 
could account for 1%-2% of all DES target vessel revasculariza-
tions.
  The incidence of stent fracture for SES and PES was 0.89% and 
0.09%, respectively in the present study. Previous data in the lit-
erature have all shown a greater incidence of stent fracture in 
SES (5, 13). This may be due to the difference in stent design 
between the two types of stents. SES with its closed cell design, 
on one hand contributes to even distribution of drug in the stent-
ed vessel, but on the other hand it is more rigid due to its closed 
cell design compared with PES, which had an open cell design. 
Hence SES is less deformable during dynamic cardiac move-
ment, resulting in transmission of shear force possibly resulting 
in breakage of stent strut. Regarding second generation DES, 
there is limited data with only one case report on ZES fracture 
(15). The Endeavor
® stent is a ZES based on the Driver
® plat-
form with its open cell design and cobalt alloy struts. Xience V
® 
is an everolimus eluting stents based on the Multi-link Vision
® 
platform, which is a cobalt chromium alloy with open cell and 
nonlinear link design making the stent flexible and more con-
formable to the vessel wall. Clinical experience must prove the 
stability of DES with open cell design regarding stent fracture.
  In the present study, we identified several risk factors on uni-
variate and multivariate analysis, such as multiple stenting, long 
stent length, chronic renal failure, implantation in RCA, SES, 
and higher maximal inflation pressure. This finding is compa-
rable to previous published data (16, 17), and a recent meta-
analysis from UCLA Medical Center (18). Mechanical stress 
may be an important factor in causing stent fracture. Liao et al. 
(19) illustrated how deployed stent resulted in vessel straight-
ening with a mean curvature decrease by 22%. Stents deployed 
in vessels with greater tortuosity such as RCA will experience 
greater straightening after stent implantation than LAD or LCX. 
This makes stents in the RCA more vulnerable to stent fracture, 
and is also consistent with our data, as 48.2% of the stent frac-
ture cases occurred in the RCA. 
  Although stent fracture was associated with an increased risk 
for TLR, stent fracture itself was not associated with significant 
symptom aggravation. Only fractured stents with binary stenosis 
lead to chest pain aggravation. Also, all of the lesions with stent 
fracture but less than 50% diameter stenosis were treated medi-
cally without any further repeat intervention, and these patients 
did very well with no adverse events up to median follow-up of 
30 months, suggesting that the natural course of stent fracture 
without significant stenosis is relatively benign. However, since 
the number of cases with stent fracture were very small, we can-
not exclude the possibility that stent fracture could predispose 
to stent thrombosis as suggested previously in anecdotal case 
reports (20). Currently stent thrombosis and in-stent restenosis 
requiring TLR are considered DES failure. Therefore the stent 
fracture might be considered as a significant risk factor for DES 
failure, even it has a benign prognosis.
  The major limitation of current study is the selection of con-
trol group for identification of predictors of stent fractures. Al-
though the predictors of stent fracture in the current study are 
concordant with results from previous studies, our study popu-
lation may not represent the real population.
  In conclusion, stent fracture is a rare complication of DES im-
plantation, which is associated with chronic renal failure, stent 
implantation in the RCA, and SES. Although its clinical course 
seems rather benign, due to the high implantation volume, it is 
associated with higher restenosis rates and repeated revascular-
ization. Precautions to avoid stent fracture need to be considered 
during PCI.
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Stent fracture (SF) has been implicated as a risk factor for in-stent restenosis (ISR), but its incidence, clinical characteristics as well 
as clinical outcome are not well established. Between 2004 and 2007, consecutive cases of SF were collected from the Seoul 
National University Hospital. Clinical characteristics and outcome of 24 patients with fractured stents were compared with a ten-
fold cohort of age and gender matched controls (n = 236). A total of 4845 patients received PCI and 3315 patients (68.4%) 
underwent angiographic follow-up. The incidence of SF was 0.89% for sirolimus-eluting stents (SES) and 0.09% for paclitaxel-
eluting stents (PES). Chronic kidney disease, stent implantation in the right coro  nary artery (RCA), and SES use were independent 
predictors of DES fracture by multivariate analysis. Although SF was significantly associated with binary restenosis and increased 
risk of target lesion revascularization, patients with SF but without significant restenosis showed excellent outcome despite only 
medical treatment. 